georgeclerk
RBC Capital Markets downgraded Bicycle Therapeutics (BCYC) to sector perform from outperform, saying “pipeline programs are taking more time to reach inflection points.”
The bank cut its price target to $11 from $27 (~36% upside based on Oct. 31 close).